TPST Tempest Therapeutics Inc

$TPST Prelim proxy for Annual Shareholder meeting. Scheduled Nov 9. https://www.sec.gov/ix?doc=/Archives/edgar/data/1544227/000121390026110304/ea0308423-pre14a_tempest.htm Proposals: 1) Elect Dr. John David Yee and Mr. William Drake Richey to the Board of Directors. 2) Ratify Ernst & Young LLP as independent registered public accounting firm. 3) Approve the issuance of more than 20% of shares in accordance with the Lincoln Park Purchase agreement 4) Approve the 3,105,591 Series C and 3,105,591 Series D warrants issued in the Sept offering Record date for the meeting is October 23, 2026. Only stockholders of record at the close on Oct 23 will be entitled to vote.

$TPST That poison pill they had running expired on Oct 10, so those 10% ownership limits are officially gone right before this big vote coming up on October 14 where management needs that 75% approval. The big milestone is Q4 when they start dosing actual patients for that TPST-4003 trial. Recently appointed Nancy Freda-Smith to the Board of Directors. Brings in corporate finance leadership usually signals a company tightening its governance structure to prepare for major institutional capital or commercial partnerships.

$TPST Just imagine if the planned Q4 human-validated in vivo trial also achieves close to 100% CR, like TPSTs ex vivo trial efficacy earlier in the year. It would be monumental. Looking forward to hearing about first person dosed soon!

$TPST Reminder as to what Proposal 1 is all about. They want to amend the Certificate of Incorporation to remove supermajority voting requirements and permit stockholder action by written consent. The proposed COI amendments are in the screenshots. Article SIXTH requires 75% shareholder approval to amend the bylaws. They want to amend it so that it only requires a shareholder majority (more than 50%) to amend the bylaws. Section 10 of Article NINTH deleted. This section currently requires 75% of all shares to approve any changes to Article NINTH. Article TENTH amended to allow stockholder action by written consent. Article TENTH currently prohibits stockholder action by written consent & requires 75% of all shares to change it. Article ELEVENTH amended to remove the provision that 75% of all shareholders are needed to amend Article ELEVENTH. Current COI for comparison: https://www.sec.gov/Archives/edgar/data/1544227/000155837019005038/mlnd-20190331ex31b53fa83.htm

$TPST - I am sure Dr. Fang and MTS has plan B. Both of them are proven top class deal maker. We can wait another 4 weeks. Novemeber would be very significant: Data release + ER + Vote + Major update on partnership/buyout. Thank you TwongStocks for updating us and going through all those piles of documents.

$TPST From an AI alert TPST takeover-defense update — October 10, 2026 Tempest’s limited-duration stockholder-rights plan—its “poison pill”—expired today as scheduled. No extension or replacement has been filed. The plan penalized unapproved ownership above 10%, or 15% for certain passive institutions. Why it matters: Removing the plan makes accumulating a substantial TPST position or pursuing an acquisition mechanically easier. It is not evidence that a takeover is pending, and Delaware’s other takeover protections remain applicable.

$TPST Did some research the firm providing the CFO is an M&A specialist now operating in a compressed time frame to conduct a valuation with a global framework for TPST 1120 and to some extent the other assets already established for me the biggest question is does Angel solely have a buyer for 1120 or does he have a plan to offload the whole show? He never intended to be a long term CEO hmmm?

$TPST Definitive proxy for Annual Meeting filed. Annual Meeting is Nov 9, not to be confused with the special meeting on Nov 12. No major changes to the preliminary proxy (see quoted post). https://www.sec.gov/ix?doc=/Archives/edgar/data/1544227/000121390026112476/ea0309613-def14a_tempest.htm Record date is Oct 23. Per the proxy, there were 19,995,358 shares outstanding as of Oct 23rd. They previously disclosed 16,889,767 shares outstanding as of Sept 21. Net gain of 3,105,591 shares. Pretty much confirms that all 3,105,591 prefunded warrants from the Sept private placement have been exercised. Would also appear that as of Oct 23, they have yet to tap into the Lincoln Park purchase agreement heavily. While the Nov 12 special meeting requires 75% of all outstanding shares to vote in favor, the proposals at the annual meeting will pass if there are more FOR votes than AGAINST, as long as there is a quorum. 9,997,680 shares must vote to establish a quorum.

$TPST $VKTX hard to say. The CEO has his issues, but he's a brilliant scientist and is doing as well as any biotech CEO probably. Manipulation of SP is rife and the shorts/bears take full advantage of the "data deserts" between trial readouts. And therein lies the only solid problem and that is that FDA trials take FOREVER and with the approval process added in, it can seem like it will be your kids that see 2735 to market. The one thing that you ABSOLUTELY CAN DEPEND ON (I think) is that VK2735 beats both Retatrutide and Terzepatide in efficacy, has a great half-life for maintenance treatments and has tolerability equal to or better than Terz and significantly better than Reta. If biotech hyperbole is true - that companies rise (or fall) on their drugs - then Viking will do very well....just gotta give it some time!

$TPST Vote YES by October 14 to clear the path for a $TPST buyout. Management has built an elite pipeline—including a 100% CAR-T response rate and a Phase 3-ready liver cancer asset—and hired Dr. Andrew Fang alongside MTS Health Partners to secure a corporate acquisition. However, outdated corporate rules are blocking the paperwork. Big Pharma buyers require a streamlined acquisition process. Voting YES lowers the voting thresholds and updates governance rules so a future takeover can happen quickly and smoothly. Why your vote is urgent: If you ignore the proxy email from your broker, it automatically counts as a NO vote. Retail apathy is accidentally stalling our own buyout premium. Search your email inbox for "Tempest Proxy" right now and vote YES / FOR on all proposals. It takes less than 60 seconds.

$TPST "I'm sorry Mr Angel, but that math ain't mathing and what you're asking me to do is unethical, so I resign". Sometimes when things look bad they really are bad. There's a trail of former CFOs here and how long has Angel been in control? Geeez. Better call Saul!

$TPST A $1B to $4B+ buyout is entirely within the historical precedent of Big Pharma acquisitions for human-validated, next-generation in-vivo cell therapy platforms. The sequence remains clear: 1) October 14, 2026: Clear the governance vote to fix the capital architecture. 2) Q4 2026: Initiate first-in-human dosing in the Senlang collaboration. 3) H1/H2 2027: Deliver human clinical proof-of-concept showing safety and deep B-cell depletion/complete responses. If step 3 delivers near-100% complete responses in humans (as per ex vivo results earlier in year), Big Pharma M&A premiums quickly turn micro-cap share counts into multi-million-pound outcomes. I'll let you do the math on the associated share price if this happens 😜

$TPST I would look for heavy pre market accumulation on Monday not saying it will happen but if it does on the heels of the poison pill exploration hmm!

$TPST Don’t we have Earnings Report this week (Nov 5th??). Fingers crossed for 1st dosing in-vivo Car-T with update.

$TPST the science of legacy and car-t seem very solid. Angel seems very solid. Cash is the glaring issue. Dilution at these levels is mere survival and won’t allow for the development that seems to be Angel’s purpose. Something has to give and soon in my opinion.

$TPST I’m up to 200k shares now btw (had 100k when I took a mental health break in August) so I still believe…I think I see a reasonable path of execution despite the current share price. Catalysts won’t come until financing structure comes to fruition after November 9 so more pain until then but after then watch out and first catalyst may even come first week of November if there is an ASH abstract. I make no predictions but I’m back before November because it is make or break time to see if the Angel team has executed or not.

$TPST well, well, well. It seems like everyone has disappeared and mostly given up. Seems about time to me. Decided I’d come back. It’s Q4 and if there is a catalyst or more than one catalyst including amezalpat ever being monetized the time to do it is immediately following the Nov. 9 shareholders’ meeting when the finance structure is unlocked and approved so the company can raise money into strength. was saying Q4 for a long time. I needed a mental health break and am now back to see if sweet Lou got it right.

$TPST TPST has been dripping the news of a deal on the table to institutional investors with a series of corporate actions and sequence of adjournments. The final signal IMO was the addition of MS. Ames she’s mathing the math. I expect a developmental PR (registration and dosage for4003?) prior to an announcement and immediate vote on a deal next week. This last signal should bring the final big dog holdouts in.

$TPST Chart simple line daily - red horizontal line: $1.25 - blue horizontal line: $0.46 Could call for $0.28-ish (I’m gonna stay on $0.46 +/- for now) An opinion

$TPST The technicals….. Can’t really call it (but a continued “drift” to a shame (lower is very possible)) Non-technicals…. Either you’re in or you’re not In the wise words of the great philosophers blaccatus sheepicus “The choice is yours”